XRAY Director Acquires 2,638 Phantom Stock Shares, April 23, 2026

Insider trading activity reveals what company leaders truly believe about their business. When executives acquire shares or deferred compensation, it signals confidence in the company’s future. Today we examine a significant insider transaction at XRAY (DENTSPLY SIRONA Inc.), a dental equipment and technology leader with a $2.4 billion market cap. Director Jonathan Jay Mazelsky recently acquired phantom stock through the company’s deferred compensation plan. This insider transaction provides insight into leadership sentiment at one of the dental industry’s most established players.

Director Acquires Phantom Stock Through Deferred Compensation Plan

Jonathan Jay Mazelsky, a director at DENTSPLY SIRONA, acquired 2,638 phantom stock units on December 31, 2025. This transaction was classified as an Award (A-Award) under SEC Form 4 filing rules. Phantom stock represents a deferred compensation arrangement where directors receive units that track the company’s actual stock value without owning real shares initially.

What Is Phantom Stock?

Phantom stock is a compensation tool used by many public companies. Directors receive units that mirror the value of actual company stock. Upon vesting or separation, these units convert to cash or real shares. This structure provides tax flexibility and aligns leadership incentives with shareholder returns. DENTSPLY SIRONA uses this mechanism to retain board talent and reward long-term commitment.

The Award Details

Mazelsky’s acquisition added 2,638 phantom stock units to his holdings. After this transaction, his total phantom stock position reached 14,382 units. The transaction occurred on December 31, 2025, and was filed with the SEC on January 2, 2026. No purchase price was disclosed because awards are granted, not purchased. This represents a meaningful addition to his deferred compensation account.

Understanding the SEC Filing and Transaction Classification

The SEC filing for this transaction was submitted as a Form 4, the standard disclosure document for insider trades. Form 4 filings must be submitted within two business days of the transaction. This particular filing shows a Change in Ownership classification, which tracks how executive compensation affects their stake in the company.

Form 4 Filing Explained

Form 4 is the SEC’s primary tool for tracking insider transactions. It captures all trades, awards, and compensation changes by company officers, directors, and major shareholders. The form requires detailed information about the security type, transaction date, and resulting ownership position. DENTSPLY SIRONA insiders file these regularly to maintain transparency with investors and regulators.

Award Transaction Type

The A-Award code indicates this was a grant or award, not a purchase or sale. Awards typically occur through compensation plans, stock option vesting, or restricted stock grants. Unlike open market transactions, awards have no market price component. They represent the company’s decision to compensate leadership through equity-based incentives. This strengthens the alignment between director interests and shareholder value.

What This Insider Activity Signals About DENTSPLY SIRONA

Director acquisitions through compensation plans reveal management confidence in the company’s direction. When leaders accept equity-based compensation, they’re betting on future performance. DENTSPLY SIRONA’s use of phantom stock shows a commitment to retaining experienced board members. The company operates in dental equipment, technology, and consumables, a stable sector with consistent demand.

Leadership Confidence Indicators

Mazelsky’s growing phantom stock position (now 14,382 units) demonstrates his continued engagement with the company. Directors who accumulate equity stakes typically believe in long-term value creation. This transaction occurred at year-end, a common timing for annual compensation awards. The size of the grant (2,638 units) reflects his board role and tenure at DENTSPLY SIRONA.

Market Context for XRAY

DENTSPLY SIRONA trades with a market cap of $2.43 billion, making it a mid-cap healthcare player. Meyka AI rates XRAY a grade of B, reflecting solid fundamentals and sector positioning. The company serves dental professionals globally with innovative equipment and digital solutions. Director compensation through phantom stock aligns with industry practices at comparable healthcare companies.

Insider Trading Trends and What Investors Should Know

This single transaction represents a buying signal, though it’s compensation-based rather than open market. One director award doesn’t indicate a major shift in insider sentiment. However, consistent equity accumulation by leadership suggests confidence in the business model. Investors should monitor whether other executives follow with similar acquisitions or sales.

Monitoring Insider Activity

Investors can track insider transactions through SEC EDGAR filings and platforms like Meyka AI. Regular monitoring reveals patterns in executive behavior. Clusters of insider buying often precede positive announcements. Conversely, concentrated selling can signal concerns. DENTSPLY SIRONA’s insider activity should be reviewed alongside quarterly earnings and industry trends.

The Bigger Picture

One phantom stock award doesn’t move the needle on investment decisions alone. However, it confirms that leadership remains committed to the company’s future. The deferred compensation structure shows DENTSPLY SIRONA values board stability and long-term thinking. Investors should view this transaction as one data point in a broader analysis of company health and direction.

Final Thoughts

Director Jonathan Jay Mazelsky’s acquisition of 2,638 phantom stock units through DENTSPLY SIRONA’s deferred compensation plan signals continued leadership confidence in the company. This Form 4 filing shows his total phantom stock position now stands at 14,382 units. While a single award doesn’t indicate major insider sentiment shifts, it confirms management commitment to the dental equipment and technology leader. DENTSPLY SIRONA’s $2.43 billion market cap and Meyka AI B grade reflect solid fundamentals. Investors should track this transaction as part of broader insider activity monitoring, alongside quarterly performance and sector trends.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Insider trading data is sourced from public SEC filings. This is not financial advice. Always conduct your own research and consult a licensed financial advisor before making investment decisions.